INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,957,600 | – | 2,000,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,814,000 | $5,191,000 | 3.20% |
| DLD Asset Management, LP | 12,500,000 | $11,219,000 | 0.70% |
| Senvest Management, LLC | 5,000,000 | $4,345,000 | 0.51% |
| Context Capital Management, LLC | 985,000 | $863,000 | 0.49% |
| LINDEN ADVISORS LP | 30,755,000 | $26,983,000 | 0.48% |
| SSI INVESTMENT MANAGEMENT LLC | 5,896,000 | $5,014,000 | 0.44% |
| BOOTHBAY FUND MANAGEMENT, LLC | 4,386,000 | $3,812,000 | 0.32% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 16,582,000 | $14,449,000 | 0.31% |
| CSS LLC/IL | 3,825,000 | $3,410,000 | 0.27% |
| Polar Asset Management Partners Inc. | 13,000,000 | $11,372,000 | 0.23% |